Drug Name: Hydralazine 1.Pharmacologic/therapeutic classification of drug: Pt.

specific
Dose: 25 mg Antihypertensive / Vasodilators drug:
Frequency: q 8hr
Route: PO 2. Mechanism of action and the end result: Patients sho
weekly and
Calculations: Reduces BP mainly by direct effect on vascular smooth retention.
muscles of arterial-resistance vessels, resulting in
vasodilation. Has little effect on venous-capacitance vessels. May occasio
Hypotensive effect may be limited by sympathetic reflexes,
which increase heart rate, stroke volume, and cardiac Monitor the
output. frequently d
and periodic
3. Pt. Specific Benefit of this drug: significant c

Vasodilation reduces peripheral resistance and substantially Make baseli

improves cardiac output, and renal and cerebral blood flow. BUN, creati
potassium, b

2. Pt. specif

Electrolyte
BP

Drug Name: Isosorbide Dinitrate 1.Pharmacologic/therapeutic classification of drug: Pt. specific

Antianginal / Nitrates drug
Dose: 10mg
Frequency: 3times 2. Mechanism of action and the end result: Make positi
Route: PO from recum
Relaxes vascular smooth muscle with a resultant decrease in dangle feet
Calculations: venous return and decrease in arterial BP, which reduces left
ventricular workload and decreases myocardial oxygen Lie down at
consumption. headedness

3. Pt. Specific Benefit of this drug: 2. Pt. specif

Has an antianginal effect by causing vasodilation of the CHF, Chest

coronary arteries.
Increase in activity tolerance.

Drug Name: Metoprolol Tartrate 1.Pharmacologic/therapeutic classification of drug: 1. Pt. specif

 this drug:
Dose: 25mg Beta adrenergic antagonist/ Antihypertensive
Frequency: q6hr Monitor hea
Route: PO 2. Mechanism of action and the end result:
Calculations: Assess and
Blocks beta-adrenergic receptors in the heart, decreasing status.
dromotropic, chronotropic, and inotropic action. Reduce HR Monitor EK
and treat HTN.

3. Pt. Specific Benefit of this drug: 2. Pt. specif

Reducesheartrateandcardiacoutputatrestandduring Patient has h

exercise;lowersbothsupineandstandingBP,slowssinus Monitor for
rateanddecreasesmyocardialautomaticity Monitor for

Drug Name: Insulin Regular 1.Pharmacologic/therapeutic classification of drug: Pt. specific

Dose: 20 unit Antidiabetic / Pancreatics drug:
Frequency: before meal
Route: subq 2. Mechanism of action and the end result: Assess patie
hypoglycem
Calculations: Lowers blood glucose by: stimulating glucose uptake in
skeletal muscle and fat, inhibiting hepatic glucose Monitor bod
production. inhibition of lipolysis and proteolysis, enhanced weight may
protein synthesis. dose

3. Pt. Specific Benefit of this drug:

2. Pt. specif
It lowers blood glucose levels by increasing peripheral
glucose uptake, especially by skeletal muscle and fat tissue, DM II
and by inhibiting the liver from changing glycogen to Glucose PO
glucose.

Drug Name: Dabigatran 1.Pharmacologic/therapeutic classification of drug: Pt. specific

Dose: 150mg drug:
Frequency: q12 Anticoagulants/ Thrombin Inhibitors
Route: PO Assess for s
2. Mechanism of action and the end result: vascular dis
Calculations: Thrombin enables the conversion
of fibrinogen into fibrin during the coagulation cascade, its Assess for s
inhibition prevents the development of a thrombus. loss

Monitor ren
 3. Pt. Specific Benefit of this drug: periodically

Lowered risk of thrombotic sequelae (stroke and systemic

embolization) of non-valvular atrial fibrillation.
2. Pt. specif
Aptt-51
Prothrombin
INR-1.3

Drug Name: Piperacillin 1.Pharmacologic/therapeutic classification of drug: 1. Pt. specif

this drug:
Dose: 100ml Anti-infective/ Extended spectrum penicillin
Frequency: q6hr Assess patie
Route: IVPB 2. Mechanism of action and the end result: and during t
Calculations:
Binds to bacterial cell wall membrane, causing cell death. Observe pat
anaphylaxis

Monitor bow
3. Pt. Specific Benefit of this drug:
Assess for s
Death of susceptible bacteria
Resolution of the signs and symptoms of infection. Length
of time for complete resolution depends on the organism 2. Pt. specif
and site of infection
Community
antibotics, A